Advertisement

Annals of Hematology

, Volume 98, Issue 8, pp 1999–2001 | Cite as

Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma

  • Ryo Nakagawa
  • Yasushi OnishiEmail author
  • Akihisa Kawajiri
  • Koichi Onodera
  • Eijiro Furukawa
  • Sayaka Sano
  • Kei Saito
  • Satoshi Ichikawa
  • Tohru Fujiwara
  • Noriko Fukuhara
  • Hideo Harigae
Letter to the Editor

Dear Editor,

Daratumumab (Dara)-containing treatments have shown promising outcomes for relapsed and refractory multiple myeloma (RRMM) [1, 2]. Dara is an antibody against CD38, which is expressed not only on myeloma cells and B cells but also on natural killer cells and activated T cells [3]. Although the necessity of prophylaxis for herpes zoster was described in previous studies of daratumumab and recent guidelines from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Compromised Hosts, cytomegalovirus (CMV) reactivation was not mentioned [4]. Recently, a few cases of CMV reactivation after Dara treatment have been reported in patients with RRMM [5, 6].

We report the cases of 5 patients with RRMM who experienced CMV reactivation after Dara-containing treatments (Table 1). We treated 13 patients with RRMM [median age, 62 (range, 47–75) years] using Dara/lenalidomide/dexamethasone ( n = 8) and Dara/bortezomib/dexamethasone ( n = 5)...

Notes

Compliance with ethical standards

This case study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766.  https://doi.org/10.1056/NEJMoa1606038 CrossRefGoogle Scholar
  2. 2.
    Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O’Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331.  https://doi.org/10.1056/NEJMoa1607751 CrossRefGoogle Scholar
  3. 3.
    van de Donk N, Richardson PG, Malavasi F (2018) CD38 antibodies in multiple myeloma: back to the future. Blood 131(1):13–29.  https://doi.org/10.1182/blood-2017-06-740944 Google Scholar
  4. 4.
    Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M (2018) ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24(Suppl 2):S83–S94.  https://doi.org/10.1016/j.cmi.2018.03.022 CrossRefGoogle Scholar
  5. 5.
    Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H (2018) Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol 101:699–702.  https://doi.org/10.1111/ejh.13164 CrossRefGoogle Scholar
  6. 6.
    Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N (2018) Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk 19:e9–e11.  https://doi.org/10.1016/j.clml.2018.10.002 CrossRefGoogle Scholar
  7. 7.
    Hasegawa T, Aisa Y, Shimazaki K, Ito C, Nakazato T (2016) Cytomegalovirus reactivation in patients with multiple myeloma. Eur J Haematol 96(1):78–82.  https://doi.org/10.1111/ejh.12551 CrossRefGoogle Scholar
  8. 8.
    Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384–394.  https://doi.org/10.1182/blood-2015-12-687749 CrossRefGoogle Scholar
  9. 9.
    Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20(4):202–213.  https://doi.org/10.1002/rmv.655 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ryo Nakagawa
    • 1
  • Yasushi Onishi
    • 1
    Email author
  • Akihisa Kawajiri
    • 1
  • Koichi Onodera
    • 1
  • Eijiro Furukawa
    • 1
  • Sayaka Sano
    • 1
  • Kei Saito
    • 1
  • Satoshi Ichikawa
    • 1
  • Tohru Fujiwara
    • 1
  • Noriko Fukuhara
    • 1
  • Hideo Harigae
    • 1
  1. 1.Department Hematology and RheumatologyTohoku University HospitalSendaiJapan

Personalised recommendations